In the News

The personalized nature of many cell therapies means organizations must be able to demonstrate to regulators that they have end to end visibility across the product supply chain to ensure chain of custody, identity and condition. Cell therapy manufacturing and supply chains need emerging information management approaches and solutions to support bringing these life changing treatments to market.